PainReform Stock Forecast, Price & News

PainReform (NASDAQ:PRFX) Frequently Asked Questions

Are investors shorting PainReform?

PainReform saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 74,400 shares, an increase of 98.4% from the October 31st total of 37,500 shares. Based on an average daily volume of 553,800 shares, the short-interest ratio is presently 0.1 days. Approximately 1.5% of the company's stock are sold short.
View PainReform's Short Interest.

When is PainReform's next earnings date?

PainReform is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for PainReform.

How were PainReform's earnings last quarter?

PainReform Ltd. (NASDAQ:PRFX) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.25.
View PainReform's earnings history.

Who are PainReform's key executives?

PainReform's management team includes the following people:

• Dr. Ehud Geller Ph.D., Exec. Chairman
• Mr. Ilan Hadar M.B.A., MBA, CEO & CFO (Age 52)
• Dr. Sigal Aviel, Chief Operating Officer (Age 57)
• Prof. Eli Hazum Ph.D., CTO & Director
• Dr. Stephen A. Cooper D.M.D Ph.D., Exec. VP of Devel.

Who are some of PainReform's key competitors?

Some companies that are related to PainReform include Capricor Therapeutics (CAPR), Akari Therapeutics (AKTX), Longboard Pharmaceuticals (LBPH), IntelGenx Technologies (IGXT), AcelRx Pharmaceuticals (ACRX), Eledon Pharmaceuticals (ELDN), Emmaus Life Sciences (EMMA), Lannett (LCI), Ocuphire Pharma (OCUP), Genprex (GNPX), Aravive (ARAV), Galecto (GLTO), Recro Pharma (REPH), Abeona Therapeutics (ABEO) and Zosano Pharma (ZSAN).
View all of PRFX's competitors.

What other stocks do shareholders of PainReform own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU).

When did PainReform IPO?

(PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.

What is PainReform's stock symbol?

PainReform trades on the NASDAQ under the ticker symbol "PRFX."

Who are PainReform's major shareholders?

PainReform's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.22%) and Citadel Advisors LLC (0.11%).

Which institutional investors are selling PainReform stock?

PRFX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.

Which institutional investors are buying PainReform stock?

PRFX stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC.

How do I buy shares of PainReform?

Shares of PRFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PainReform's stock price today?

One share of PRFX stock can currently be purchased for approximately $1.94.

How much money does PainReform make?

PainReform has a market capitalization of $20.34 million.

How many employees does PainReform have?

PainReform employs 2 workers across the globe.

What is PainReform's official website?

The official website for PainReform is www.painreform.com.

How can I contact PainReform?

The company can be reached via phone at 972-9960-1901 or via email at [email protected].